A novel perspective for an orphan problem: old and new drugs for the medical management of malignant ascites.

[1]  K. Rühle,et al.  Treatment of Malignant Pleural Effusion With the Trifunctional Antibody Catumaxomab (Removab) (Anti-EpCAM×Anti-CD3): Results of a Phase 1/2 Study , 2009, Journal of immunotherapy.

[2]  P. Mhawech-Fauceglia,et al.  The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report. , 2008, Gynecologic oncology.

[3]  Mildred R. Chernofsky,et al.  Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. , 2008, Gynecologic oncology.

[4]  J. Esquivel,et al.  Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination , 2008, Journal of surgical oncology.

[5]  Wiley Interscience,et al.  Locoregional treatment of peritoneal carcinomatosis from gastric cancer , 2008, Journal of surgical oncology.

[6]  M. Deraco,et al.  The Fifth International Workshop on Peritoneal Surface Malignancy (Milan, Italy, December 4–6, 2006): methodology of disease‐specific consensus , 2008, Journal of surgical oncology.

[7]  R. Bristow,et al.  Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer , 2008, Journal of surgical oncology.

[8]  A. Burges,et al.  Pharmacokinetics and in vivo stability of intraperitoneally administered therapeutic antibody catumaxomab , 2008 .

[9]  Hyo-jin Kim,et al.  A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. , 2007, Japanese journal of clinical oncology.

[10]  H. Ueno,et al.  FP therapy for controlling malignant ascites in advanced pancreatic cancer patients. , 2007, Hepato-gastroenterology.

[11]  R. Kimmig,et al.  Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study , 2007, Clinical Cancer Research.

[12]  M. Gore,et al.  Treatment of ovarian cancer patients with malignant ascites using the trifunctional antibody catumaxomab: Results of a phase II/III study , 2007 .

[13]  S. Loibl,et al.  Randomized, multicenter, two-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients , 2007 .

[14]  S. Parsons,et al.  Pattern and prognostic factors in patients with malignant ascites: a retrospective study. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  E. Thiel,et al.  Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM × anti-CD3): a phase I study , 2007, Cancer Immunology, Immunotherapy.

[16]  A. Reuss,et al.  The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  M. Barnes,et al.  The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. , 2006, Gynecologic oncology.

[18]  P. Sugarbaker,et al.  Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[19]  K. Jauch,et al.  Efficacy of intraperitoneal treatment with the trifunctional antibody catumaxomab in patients with GI-tract cancer and peritoneal carcinomatosis: A matched-pair analysis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Timothy Zhu,et al.  A Phase II Trial of Intraperitoneal Photodynamic Therapy for Patients with Peritoneal Carcinomatosis and Sarcomatosis , 2006, Clinical Cancer Research.

[21]  G. Becker,et al.  Malignant ascites: systematic review and guideline for treatment. , 2006, European journal of cancer.

[22]  V. Varney,et al.  The successful treatment of chylous effusions in malignant disease with octreotide. , 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

[23]  D. Kelsen,et al.  Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma , 2005, Journal of Cancer Research and Clinical Oncology.

[24]  Y. Adam,et al.  Malignant ascites: past, present, and future. , 2004, Journal of the American College of Surgeons.

[25]  C. Karapetis,et al.  Matrix Metalloproteinase Inhibitors: Applications in Oncology , 2004, Investigational New Drugs.

[26]  K. Shimizu,et al.  Locoregional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK-432 plus Interleukin-2 , 2003, British Journal of Cancer.

[27]  I. Runnebaum,et al.  Intraperitoneal chemotherapy with mitoxantrone in malignant ascites. , 2003, Surgical oncology clinics of North America.

[28]  K. Geisinger,et al.  Prospective Trial for the Treatment of Malignant Peritoneal Mesothelioma , 2001, The American surgeon.

[29]  P. Malacarne,et al.  Evaluation of a Standardized Protocol of Intracavitary Recombinant Interferon Alpha-2b in the Palliative Treatment of Malignant Peritoneal Effusions , 2001, Oncology.

[30]  K. Geisinger,et al.  Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy for Disseminated Peritoneal Cancer of Gastrointestinal Origin , 2000, The American surgeon.

[31]  J. Mackey,et al.  A phase II trial of triamcinolone hexacetanide for symptomatic recurrent malignant ascites. , 2000, Journal of pain and symptom management.

[32]  P. McNamara,et al.  Paracentesis – an effective method of symptom control in the palliative care setting? , 2000, Palliative medicine.

[33]  H. Suzuki,et al.  Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo. , 2000, Anticancer Research.

[34]  R. Malone,et al.  Octreotide as an agent for the relief of malignant ascites in palliative care patients , 1999, Palliative medicine.

[35]  T. Morisaki,et al.  The past, the present and future of the OK-432 therapy for patients with malignant effusions. , 1998, Anticancer research.

[36]  W. Faught,et al.  A survey of practice in management of malignant ascites. , 1998, Journal of pain and symptom management.

[37]  J. Smyth,et al.  Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  R. Steele,et al.  Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. , 1997, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[39]  J. Bienvenu,et al.  [Intraperitoneal chemo-hyperthermia with mitomycin C in cancer of the stomach with peritoneal carcinosis]. , 1997, Journal de chirurgie.

[40]  K. Geisinger,et al.  Treatment and prevention of malignant ascites associated with disseminated intraperitoneal malignancies by aggressive combined-modality therapy. , 1997, The American surgeon.

[41]  J. Carmichael,et al.  A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma. , 1997, Gynecologic oncology.

[42]  R. Steele,et al.  Malignant ascites: a 2-year review from a teaching hospital. , 1996, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[43]  S. L. Parsons,et al.  Malignant ascites , 1996, The British journal of surgery.

[44]  A. Maiche.  Management of peritoneal effusions with intracavitary mitoxantrone or bleomycin. , 1994, Anti-Cancer Drugs.

[45]  N. Gebbia,et al.  Intracavitary treatment of malignant pleural and peritoneal effusions in cancer patients. , 1994, Anticancer Research.

[46]  T. Nakagoe,et al.  [Continuous hyperthermic peritoneal perfusion (CHPP) for prevention or treatment of peritoneal dissemination]. , 1993, Gan to kagaku ryoho. Cancer & chemotherapy.

[47]  G. Stuart,et al.  Intraperitoneal interferon in the management of malignant ascites , 1993, Cancer.

[48]  J. Bienvenu,et al.  Treatment of malignant peritoneal effusion in digestive and ovarian cancer , 1992, Medical oncology and tumor pharmacotherapy.

[49]  G. Bastert,et al.  Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites. , 1991, European journal of cancer.

[50]  R. Schilsky,et al.  Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  W. Bezwoda,et al.  Intraperitoneal recombinant interferon‐alpha 2b for recurrent malignant ascites due to ovarian cancer , 1989 .

[52]  L. Seymour,et al.  Intraperitoneal recombinant interferon-alpha 2b for recurrent malignant ascites due to ovarian cancer. , 1989, Cancer.

[53]  J. McCormick,et al.  Corticosteroids in COPD. A clinical trial and reassessment of the literature. , 1986, Chest.

[54]  M. Ostrowski.  An assessment of the long‐term results of controlling the reaccumulation of malignant effusions using intracavity bleomycin , 1986, Cancer.

[55]  D. Tarin,et al.  Peritoneovenous shunts in the management of malignant ascites , 1983, The British journal of surgery.

[56]  W. Creasman,et al.  Intracavitary Corynebacterium parvum for treatment of malignant effusions. , 1983, Gynecologic oncology.

[57]  L. Salmela,et al.  On the treatment and prognosis of malignant ascites: Is the survival time determined when the abdominal paracentesis is needed? , 1982, Journal of surgical oncology.

[58]  M. Katano,et al.  New approach to management of malignant ascites with a streptococcal preparation, OK-432. II. Intraperitoneal inflammatory cell-mediated tumor cell destruction. , 1983, Surgery.

[59]  H. Itoh,et al.  New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival. , 1983, Surgery.

[60]  K. Cantell,et al.  Human leukocyte interferon therapy for advanced ovarian carcinoma. , 1982, American journal of clinical oncology.

[61]  E. Savlov,et al.  Peritoneovenous shunt for palliation of malignant ascites , 1982, Cancer.

[62]  A. Taylor,et al.  Loculation as a contraindication intracavitary 32P-chromic phosphate therapy. , 1975, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[63]  G. Pack,et al.  Intracavitary administration of radioactive isotopes in the control of effusions due to cancer: Results in 267 patients , 1966, Cancer.

[64]  Card Ry,et al.  Summary of ten years of the use of radioactive colloids in intracavitary therapy. , 1960 .

[65]  O. Balchum,et al.  Treatment of pleural and peritoneal effusion with intracavitary colloidal radiogold (Au 198). , 1959, Archives of internal medicine.

[66]  M. L. Jacobs.  Radioactive colloidal chromic phosphate to control pleural effusion and ascites. , 1958, Journal of the American Medical Association.

[67]  J. Storaasli,et al.  Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. , 1955, Journal of the American Medical Association.